Stryker Acquires Inari Medical for $4.9 Billion to Accelerate Cardiovascular and Neurovascular Expansion

Jan 07, 2025 09:30 CST Updated 09:30

Inari Medical

Cardiovascular Disease Treatment Device Developer

Stryker

Medical Device R&D, Production, and Sales Company

Stryker announcedAcquisition at $80 per share in cashInari medical(Approximately 4.9 billion USD, Stryker is really wealthy). This is the first major acquisition exceeding 1 billion USD in the new year of 2025, setting a good start for the subsequent M&A market in 2025. This acquisition also marks Stryker's official entry into the peripheral market and will highly complement Stryker's strong neurointervention product line.

Executive Evaluation

"The acquisition of Inari expands Stryker's product portfolio, providing life-saving solutions for patients with peripheral vascular disease. These innovations raise the standard of care for patients with venous thromboembolism and will accelerate Stryker's impact in endovascular procedures."

---Kevin Lobo, Chairman and Chief Executive Officer of Stryker

"Inari has positively impacted the lives of hundreds of thousands of patients by developing tools specifically targeting unmet patient needs. With Stryker's capabilities and global infrastructure, we will be better able to accelerate the development of innovative solutions and expand our footprint."

---Drew Hykes, CEO of Inari Medical

Inari medicalYesVenous Thromboembolism (VTE)Domain Leader.Venous Thromboembolism (VTE) is a rapidly growing field,According to data from the U.S. Centers for Disease Control and Prevention, venous thromboembolism affects up to 900,000 people annually in the United States, with more than 100,000 deaths occurring as a result, causing...$10 billion in medical cost lossesMoreover, this data is likely to be underestimated because pulmonary embolism can lead to unexplained sudden cardiac death.

Inari medicalAs a leader in this field, Inari Medical has pioneered many new mechanical thrombectomy technologies, providing clear embolization solutions for patients who cannot be treated with drug thrombolysis.For this reasonInari medicalIn this field, it has absolute say, and its performance also reflects its position in the industry.Inari medicalThe announcement of the third-quarter results for 2024 showed sales of $153.4 million, a year-over-year increase of 21%. The market expects its total sales for 2024 to exceed $600 million. Achieving over $600 million in sales is quite an accomplishment for a company with a relatively single product line.

A rapidly growing and leading company is absolutely the best target for large companies to acquire. Stryker seized the opportunity, therebyObtainInari medical。This is Stryker's continuedAcquisition in 2011Following its neurointervention business, Boston Scientific makes another major acquisition in the cardiovascular field.Will alsoStrykergFutureRapid GrowthProvideNew momentum, while also laying the foundation for Stryker to become a giant in the cardiovascular field.

Inari Medical Classic Products

FlowTriever

FlowTrieverIt is the first FDA-approved mechanical thrombectomy system for the treatment of pulmonary embolism, designed to rapidly remove blood clots and immediately improve symptoms in patients with acute pulmonary embolism.

ClotTriever

ClotTrieverIt is a mechanical thrombectomy device specifically designed for the treatment of deep vein thrombosis (DVT).

RevCore

RevCoreIs the first mechanical thrombectomy device for venous stents, designed to address the issue of venous thrombosis within stents, which canTreating vessels with a diameter of more than 6mm or venous stents with a diameter of 10 to 20mm.

Artix

ArtiYesInari medicalFor emergency useLower extremity ischemia lacks effective solutions,Can effectively clear thrombosis and alleviate the symptoms of these potential and urgent conditions.

LimFlow System

LimFlow SystemYesInari MedicalAcquired for $400 million, it is the world's first FDA-approved deep vein transcatheter arterialization product, which can be used to treat patients with chronic limb-threatening ischemia (CLTI).

Inari Medical

Inari MedicalIt is an innovative medical device company focused on developing products that treat patients with venous diseases and transform their lives.